EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ ALL pediatric patients with high minimal residual disease

Antonio Lahera iD, Laura Vela-Martín, Pablo Fernández-Navarro, José Luis López-Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez-Gómez iD, José Luis Marín-Rubio, Manuel Fresno iD, Javier Santos, José Fernández-Piqueras iD, María Villa-Morales iD

Molecular Oncology · 2026-11 · 20 (11) · 2637-2646

DOI: 10.1002/1878-0261.70234 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 09.04.2026. Verfasst von Antonio Lahera und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Universidad Autónoma de Madrid, Spain. Hauptthemen laut MEDLINE: Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Gene Expression Regulation, Leukemic, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, NCI NIH HHS, Instituto de Investigación Sanitaria Fundación Jiménez Díaz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T‐cell acute lymphoblastic leukemia (T‐ALL) originates from the malignant transformation of immature lymphoblasts committed to the T‐cell lineage. Relapsed or refractory T‐ALL patients show a dismal outcome with limited therapeutic options and cure rates below 10%. Accurate risk stratification is essential for optimizing first‐line treatments and maximizing initial complete response rates. Minimal residual disease (MRD) assessment is the most relevant clinical parameter in T‐ALL and a direct measure of treatment response, but it requires an initial treatment course that reduces the time for decision‐making. Consequently, there is an urgent need to identify novel biomarkers that can predict the response to first‐line treatments at diagnosis. By integrating clinical and transcriptomic data from diagnostic T‐ALL samples, we found that high MRD patients show a specific transcriptional profile. Moreover, we identified a transcriptional signature characterized by the differential expression of HSH2D , LAT2 , BCL2 , MAST4 , METRN , and PITPNM2 genes that is tightly associated with an increased MRD, which could improve the prediction of poor treatment response in T‐ALL patients, especially during early treatment phases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualPrecursor T-Cell Lymphoblastic Leukemia-LymphomaGene Expression Regulation, LeukemicGene Expression Regulation, NeoplasticHumansChildFemaleMaleGene Expression ProfilingTreatment OutcomeChild, PreschoolBiomarkers, Tumor

Stichwörter der Autor:innen

T‐cell acute lymphoblastic leukemia (T‐ALL)early biomarkerminimal residual disease (MRD)response to therapy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Molecular Biology, Universidad Autónoma de Madrid, Spain.
  • Centro de Biologia Molecular Severo Ochoa (CBM), CSIC - Universidad Autonoma de Madrid, Spain.
  • Department of Biology, Universidad Autónoma de Madrid, Spain.
  • Area of Genetics and Genomics, IIS Fundación Jiménez Díaz, Madrid, Spain.
  • Unit of Cancer and Environmental Epidemiology, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
  • Networking Biomedical Research Centre of Epidemiology and Public Health (CIBERESP), Madrid, Spain.

ORCID-Profile: Antonio Lahera, Eduardo Pérez-Gómez, Manuel Fresno, José Fernández-Piqueras, María Villa-Morales

Förderung

  • Ministerio de Ciencia, Innovación y Universidades
  • NCI NIH HHS
  • Instituto de Investigación Sanitaria Fundación Jiménez Díaz
  • Ministerio de Ciencia e Innovación

Zitieren

APA

Lahera, A., Vela-Martín, L., Fernández-Navarro, P., López-Lorenzo, J. L., Cornago, J., Llamas, P., Pérez-Gómez, E., Marín-Rubio, J. L., Fresno, M., Santos, J., Fernández-Piqueras, J., & Villa-Morales, M. (2026). Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ ALL pediatric patients with high minimal residual disease. Molecular Oncology, 20(11), 2637-2646. https://doi.org/10.1002/1878-0261.70234

Vancouver

Lahera A, Vela-Martín L, Fernández-Navarro P, López-Lorenzo JL, Cornago J, Llamas P, et al. Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ ALL pediatric patients with high minimal residual disease. Molecular Oncology. 2026;20(11):2637-2646. doi:10.1002/1878-0261.70234

BibTeX
@article{Lahera2026,
  author = {Lahera, Antonio and Vela-Martín, Laura and Fernández-Navarro, Pablo and López-Lorenzo, José Luis and Cornago, Javier and Llamas, Pilar and Pérez-Gómez, Eduardo and Marín-Rubio, José Luis and Fresno, Manuel and Santos, Javier and Fernández-Piqueras, José and Villa-Morales, María},
  title = {Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ ALL pediatric patients with high minimal residual disease},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {11},
  pages = {2637--2646},
  doi = {10.1002/1878-0261.70234}
}
Kostenlos starten →